Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Jun;10(Suppl 17):S2086-S2088.
doi: 10.21037/jtd.2018.05.37.

Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma

Yasuo Hamamoto  1
Affiliations
Comment

Need for prospective collection of experience and repeated samples in esophageal squamous cell carcinoma

Yasuo Hamamoto. J Thorac Dis. 2018 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Strategy for investigation of esophageal squamous cell carcinoma.
See this image and copyright information in PMC

Comment on

References

    1. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 2017;18:631-9. 10.1016/S1470-2045(17)30181-X - DOI - PubMed
    1. Doi T, Piha-Paul SA, Jalal SI, et al. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. J Clin Oncol 2018;36:61-7. 10.1200/JCO.2017.74.9846 - DOI - PubMed
    1. Shaverdian N, Lisberg AE, Bornazyan K, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 2017;18:895-903. 10.1016/S1470-2045(17)30380-7 - DOI - PMC - PubMed
    1. Okamura A, Takeuchi H, Matsuda S, et al. Factors affecting cytokine change after esophagectomy for esophageal cancer. Ann Surg Oncol 2015;22:3130-5. 10.1245/s10434-014-4348-4 - DOI - PubMed
    1. Schvartsman G, Peng SA, Bis G, et al. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 2017;112:90-5. 10.1016/j.lungcan.2017.07.034 - DOI - PubMed

LinkOut - more resources